MMJ BioPharma vs. the DEA: A Long Fight Over Cannabis Research

How one company's licensing dispute became a constitutional case.

For years, a pharmaceutical company called MMJ BioPharma Cultivation has been locked in a legal dispute with the U.S. Drug Enforcement Administration (DEA) over its efforts to study cannabis-based treatments for multiple sclerosis (MS) and Huntington's disease (HD). What began as a licensing delay has grown into a case with broader implications for how federal agencies operate.

The Core Dispute

MMJ BioPharma says it has been waiting since December 2018 for DEA authorization to legally cultivate pharmaceutical-grade cannabis for use in FDA clinical trials. The company states that it has met the regulatory requirements to move forward — including filing two Investigational New Drug (IND) applications with the FDA and earning Orphan Drug Designations for its MS and Huntington's programs — but that the DEA has not acted on its application in a reasonable timeframe.

MMJ argues that this prolonged delay has caused it significant financial harm and, more importantly, held back research that could matter to patients with serious neurological conditions. The DEA, for its part, has taken the position in this dispute that no final decision has been made and that the company has not yet satisfied all conditions for approval. The available public record of the case draws heavily on MMJ's own filings and statements, so the company's characterizations are its own.

The Constitutional Turn

The most consequential part of the case concerns the DEA's internal court system. MMJ challenged the DEA's use of administrative law judges (ALJs) — in-house judges who hear agency disputes — arguing that the system denied it a fair, impartial hearing. The company's challenge leaned on recent Supreme Court decisions, Axon v. FTC and Jarkesy v. SEC, which found that federal agencies had improperly shielded their in-house judicial systems from constitutional accountability.

This argument gained significant ground. By late 2025, the Department of Justice had effectively conceded that the DEA's administrative law judge structure was invalid. That's a notable outcome: a complaint that started as one company's objection ended up contributing to a broader reckoning over how agency tribunals are constituted.

Why It Matters

Beyond MMJ BioPharma's own interests, the case touches two larger themes. One is the long-standing bottleneck in U.S. cannabis research: even as attitudes and laws shift, federal licensing has remained a slow and complicated path for companies trying to run legitimate clinical trials. The other is procedural — the question of whether federal agencies can act as both regulator and judge in their own disputes.

The litigation has been lengthy and has involved multiple filings and several DEA administrators over its course, reflecting how long these disputes can run. For patients and families watching cannabis research move slowly through the federal system, cases like this one are a reminder that the path from laboratory to approved treatment is shaped as much by regulatory and legal process as by the science itself.

This article is for general information only and is not legal advice. It summarizes an ongoing legal dispute based on publicly available reporting, much of which originates from the company involved. Details of active litigation can change.

Last reviewed: May 2026.